Research and Development<\/h4><\/div>New biomaterials, technology platforms and treatment concepts.<\/h1><\/div>We are actively shaping the future state of art, so that new treatment concepts and new biomaterials help to improve patient well-being. biotrics invests substantially in innovative development projects and new technology platforms. We are able to take a product from its idea to market maturity and through approval.<\/p>\n<\/div><\/div><\/div><\/div><\/div>
![](\"https:\/\/biotrics.com\/wp-content\/uploads\/2022\/10\/screenshot-video-h-bearb.png\" "\\"screenshot-video-h-bearb\\"")
<\/span><\/div><\/div><\/div>The choice of raw material determines the product and its applications… and vice versa. <\/span><\/h3><\/div>Depending on the desired indication, we carefully select the raw material within the development phase. Based on our many years of experience, we master a wide range of processing technologies in our factory. We can therefore both set and control the desired product properties. During development, we always keep our mission of “regenerating instead of substituting” in mind and develop in compliance with the physiological processes of the human body.<\/p>\n<\/div>
<\/i>Our mission<\/span><\/a><\/div><\/div><\/div><\/div><\/div>Ongoing projects<\/h2><\/div>Our development always takes place through exchanges with clinical and university partners.<\/h3><\/div>We highly value the opinion of experts and are also prepared to break new ground. Thanks to the support of both the Federal Ministry of Education and Research (BMBF) and the Federal Ministry of Economics and Climate Protection (BMWK), we are also in a position to pursue these paths. <\/span><\/p>\n<\/div><\/div><\/div><\/i><\/i><\/span>ElastGraft<\/span><\/a><\/h4><\/div>\nProject Title:<\/h6>\nDevelopment of a natural vascular substitute for complete regeneration of deficient vessel sections based on porcine elastin-containing graft materials (ElastGraft) (FKZ: KK5025303NK1, BMWi)<\/h3>\n
Various vascular diseases such as arteriosclerosis with its sequelae, congenital vascular anomalies or injuries require conservative as well as sometimes surgical intervention. Surgical replacement of vessels can take place using various biomaterials. The problem is that the available materials cannot replicate the natural vessel architecture. The overall goal of this collaborative project is to develop an innovative natural-based vascular substitute for the complete regeneration and replication of complex vascular structures.<\/p>\n<\/div><\/div><\/div>
<\/i><\/i><\/span>Hemostasis through topological structures<\/span><\/a><\/h4><\/div>\nProject Title:<\/h6>\nHemomatrix<\/h3>\n
During the surgical procedure, bleeding is a disruption and sometimes even a challenge for the surgeon. On the one hand, blood loss must be limited, and on the other hand, blood obscures the view of the surgical area. In certain surgical areas, the choice falls on topological hemostats. The aim of this project is to develop an absorbable medical device that is able to reliably stop oozing and is also allowed to remain in the implantation site. <\/span><\/p>\n<\/div><\/div><\/div><\/i><\/i><\/span>Control options for resorption profiles<\/span><\/a><\/h4><\/div>\n\nThe need for control regarding resorption profiles of implants is the subject of our expert feedback. In our experience, a variety of factors affect the degradation behavior. Bacterial contamination in the wound cavity is one of the main causes leading to a change in the resorption profiles of our products. The overall objective of this project is to develop a control option to adjust the resorption profiles of biotrics products and their behavior towards enzymatic degradation and different wound situations. <\/span><\/p>\n<\/div>\n<\/div><\/div><\/div><\/i><\/i><\/span>Bone graft substitutes with defined release of active substances<\/span><\/a><\/h4><\/div>\nProject Title:<\/h6>\nOKEM (FKZ: 13GW0430A, BMBF).<\/h3>\n
Osteitis is one of the most common and serious nosocomial infections, occurring primarily through direct infection during bone surgery. Treatment is difficult and often associated with long-term, significant disadvantages for the patient, including amputations. OKEM aims to develop a technology for the functionalization of bone graft substitutes (KEM) that enables the controlled release of active substances in the body directly at the implanted KEM, thus reliably and efficiently counteracting nosocomial infection in the form of osteitis. <\/p>\n<\/div><\/div><\/div>
New biomaterials, technology platforms and treatment concepts.<\/h1><\/div>We are actively shaping the future state of art, so that new treatment concepts and new biomaterials help to improve patient well-being. biotrics invests substantially in innovative development projects and new technology platforms. We are able to take a product from its idea to market maturity and through approval.<\/p>\n<\/div><\/div><\/div><\/div><\/div>
<\/span><\/div><\/div><\/div>The choice of raw material determines the product and its applications… and vice versa. <\/span><\/h3><\/div>Depending on the desired indication, we carefully select the raw material within the development phase. Based on our many years of experience, we master a wide range of processing technologies in our factory. We can therefore both set and control the desired product properties. During development, we always keep our mission of “regenerating instead of substituting” in mind and develop in compliance with the physiological processes of the human body.<\/p>\n<\/div>
<\/i>Our mission<\/span><\/a><\/div><\/div><\/div><\/div><\/div>Ongoing projects<\/h2><\/div>Our development always takes place through exchanges with clinical and university partners.<\/h3><\/div>We highly value the opinion of experts and are also prepared to break new ground. Thanks to the support of both the Federal Ministry of Education and Research (BMBF) and the Federal Ministry of Economics and Climate Protection (BMWK), we are also in a position to pursue these paths. <\/span><\/p>\n<\/div><\/div><\/div><\/i><\/i><\/span>ElastGraft<\/span><\/a><\/h4><\/div>\nProject Title:<\/h6>\nDevelopment of a natural vascular substitute for complete regeneration of deficient vessel sections based on porcine elastin-containing graft materials (ElastGraft) (FKZ: KK5025303NK1, BMWi)<\/h3>\n
Various vascular diseases such as arteriosclerosis with its sequelae, congenital vascular anomalies or injuries require conservative as well as sometimes surgical intervention. Surgical replacement of vessels can take place using various biomaterials. The problem is that the available materials cannot replicate the natural vessel architecture. The overall goal of this collaborative project is to develop an innovative natural-based vascular substitute for the complete regeneration and replication of complex vascular structures.<\/p>\n<\/div><\/div><\/div>
<\/i><\/i><\/span>Hemostasis through topological structures<\/span><\/a><\/h4><\/div>\nProject Title:<\/h6>\nHemomatrix<\/h3>\n
During the surgical procedure, bleeding is a disruption and sometimes even a challenge for the surgeon. On the one hand, blood loss must be limited, and on the other hand, blood obscures the view of the surgical area. In certain surgical areas, the choice falls on topological hemostats. The aim of this project is to develop an absorbable medical device that is able to reliably stop oozing and is also allowed to remain in the implantation site. <\/span><\/p>\n<\/div><\/div><\/div><\/i><\/i><\/span>Control options for resorption profiles<\/span><\/a><\/h4><\/div>\n\nThe need for control regarding resorption profiles of implants is the subject of our expert feedback. In our experience, a variety of factors affect the degradation behavior. Bacterial contamination in the wound cavity is one of the main causes leading to a change in the resorption profiles of our products. The overall objective of this project is to develop a control option to adjust the resorption profiles of biotrics products and their behavior towards enzymatic degradation and different wound situations. <\/span><\/p>\n<\/div>\n<\/div><\/div><\/div><\/i><\/i><\/span>Bone graft substitutes with defined release of active substances<\/span><\/a><\/h4><\/div>\nProject Title:<\/h6>\nOKEM (FKZ: 13GW0430A, BMBF).<\/h3>\n
Osteitis is one of the most common and serious nosocomial infections, occurring primarily through direct infection during bone surgery. Treatment is difficult and often associated with long-term, significant disadvantages for the patient, including amputations. OKEM aims to develop a technology for the functionalization of bone graft substitutes (KEM) that enables the controlled release of active substances in the body directly at the implanted KEM, thus reliably and efficiently counteracting nosocomial infection in the form of osteitis. <\/p>\n<\/div><\/div><\/div>
We are actively shaping the future state of art, so that new treatment concepts and new biomaterials help to improve patient well-being. biotrics invests substantially in innovative development projects and new technology platforms. We are able to take a product from its idea to market maturity and through approval.<\/p>\n<\/div><\/div><\/div><\/div><\/div>
<\/span><\/div><\/div><\/div>The choice of raw material determines the product and its applications… and vice versa. <\/span><\/h3><\/div>Depending on the desired indication, we carefully select the raw material within the development phase. Based on our many years of experience, we master a wide range of processing technologies in our factory. We can therefore both set and control the desired product properties. During development, we always keep our mission of “regenerating instead of substituting” in mind and develop in compliance with the physiological processes of the human body.<\/p>\n<\/div>
<\/i>Our mission<\/span><\/a><\/div><\/div><\/div><\/div><\/div>Ongoing projects<\/h2><\/div>Our development always takes place through exchanges with clinical and university partners.<\/h3><\/div>We highly value the opinion of experts and are also prepared to break new ground. Thanks to the support of both the Federal Ministry of Education and Research (BMBF) and the Federal Ministry of Economics and Climate Protection (BMWK), we are also in a position to pursue these paths. <\/span><\/p>\n<\/div><\/div><\/div><\/i><\/i><\/span>ElastGraft<\/span><\/a><\/h4><\/div>\nProject Title:<\/h6>\nDevelopment of a natural vascular substitute for complete regeneration of deficient vessel sections based on porcine elastin-containing graft materials (ElastGraft) (FKZ: KK5025303NK1, BMWi)<\/h3>\n
Various vascular diseases such as arteriosclerosis with its sequelae, congenital vascular anomalies or injuries require conservative as well as sometimes surgical intervention. Surgical replacement of vessels can take place using various biomaterials. The problem is that the available materials cannot replicate the natural vessel architecture. The overall goal of this collaborative project is to develop an innovative natural-based vascular substitute for the complete regeneration and replication of complex vascular structures.<\/p>\n<\/div><\/div><\/div>
<\/i><\/i><\/span>Hemostasis through topological structures<\/span><\/a><\/h4><\/div>\nProject Title:<\/h6>\nHemomatrix<\/h3>\n
During the surgical procedure, bleeding is a disruption and sometimes even a challenge for the surgeon. On the one hand, blood loss must be limited, and on the other hand, blood obscures the view of the surgical area. In certain surgical areas, the choice falls on topological hemostats. The aim of this project is to develop an absorbable medical device that is able to reliably stop oozing and is also allowed to remain in the implantation site. <\/span><\/p>\n<\/div><\/div><\/div><\/i><\/i><\/span>Control options for resorption profiles<\/span><\/a><\/h4><\/div>\n\nThe need for control regarding resorption profiles of implants is the subject of our expert feedback. In our experience, a variety of factors affect the degradation behavior. Bacterial contamination in the wound cavity is one of the main causes leading to a change in the resorption profiles of our products. The overall objective of this project is to develop a control option to adjust the resorption profiles of biotrics products and their behavior towards enzymatic degradation and different wound situations. <\/span><\/p>\n<\/div>\n<\/div><\/div><\/div><\/i><\/i><\/span>Bone graft substitutes with defined release of active substances<\/span><\/a><\/h4><\/div>\nProject Title:<\/h6>\nOKEM (FKZ: 13GW0430A, BMBF).<\/h3>\n
Osteitis is one of the most common and serious nosocomial infections, occurring primarily through direct infection during bone surgery. Treatment is difficult and often associated with long-term, significant disadvantages for the patient, including amputations. OKEM aims to develop a technology for the functionalization of bone graft substitutes (KEM) that enables the controlled release of active substances in the body directly at the implanted KEM, thus reliably and efficiently counteracting nosocomial infection in the form of osteitis. <\/p>\n<\/div><\/div><\/div>
Depending on the desired indication, we carefully select the raw material within the development phase. Based on our many years of experience, we master a wide range of processing technologies in our factory. We can therefore both set and control the desired product properties. During development, we always keep our mission of “regenerating instead of substituting” in mind and develop in compliance with the physiological processes of the human body.<\/p>\n<\/div>
Ongoing projects<\/h2><\/div>Our development always takes place through exchanges with clinical and university partners.<\/h3><\/div>We highly value the opinion of experts and are also prepared to break new ground. Thanks to the support of both the Federal Ministry of Education and Research (BMBF) and the Federal Ministry of Economics and Climate Protection (BMWK), we are also in a position to pursue these paths. <\/span><\/p>\n<\/div><\/div><\/div><\/i><\/i><\/span>ElastGraft<\/span><\/a><\/h4><\/div>\nProject Title:<\/h6>\nDevelopment of a natural vascular substitute for complete regeneration of deficient vessel sections based on porcine elastin-containing graft materials (ElastGraft) (FKZ: KK5025303NK1, BMWi)<\/h3>\n
Various vascular diseases such as arteriosclerosis with its sequelae, congenital vascular anomalies or injuries require conservative as well as sometimes surgical intervention. Surgical replacement of vessels can take place using various biomaterials. The problem is that the available materials cannot replicate the natural vessel architecture. The overall goal of this collaborative project is to develop an innovative natural-based vascular substitute for the complete regeneration and replication of complex vascular structures.<\/p>\n<\/div><\/div><\/div>
<\/i><\/i><\/span>Hemostasis through topological structures<\/span><\/a><\/h4><\/div>\nProject Title:<\/h6>\nHemomatrix<\/h3>\n
During the surgical procedure, bleeding is a disruption and sometimes even a challenge for the surgeon. On the one hand, blood loss must be limited, and on the other hand, blood obscures the view of the surgical area. In certain surgical areas, the choice falls on topological hemostats. The aim of this project is to develop an absorbable medical device that is able to reliably stop oozing and is also allowed to remain in the implantation site. <\/span><\/p>\n<\/div><\/div><\/div><\/i><\/i><\/span>Control options for resorption profiles<\/span><\/a><\/h4><\/div>\n\nThe need for control regarding resorption profiles of implants is the subject of our expert feedback. In our experience, a variety of factors affect the degradation behavior. Bacterial contamination in the wound cavity is one of the main causes leading to a change in the resorption profiles of our products. The overall objective of this project is to develop a control option to adjust the resorption profiles of biotrics products and their behavior towards enzymatic degradation and different wound situations. <\/span><\/p>\n<\/div>\n<\/div><\/div><\/div><\/i><\/i><\/span>Bone graft substitutes with defined release of active substances<\/span><\/a><\/h4><\/div>\nProject Title:<\/h6>\nOKEM (FKZ: 13GW0430A, BMBF).<\/h3>\n
Osteitis is one of the most common and serious nosocomial infections, occurring primarily through direct infection during bone surgery. Treatment is difficult and often associated with long-term, significant disadvantages for the patient, including amputations. OKEM aims to develop a technology for the functionalization of bone graft substitutes (KEM) that enables the controlled release of active substances in the body directly at the implanted KEM, thus reliably and efficiently counteracting nosocomial infection in the form of osteitis. <\/p>\n<\/div><\/div><\/div>
Our development always takes place through exchanges with clinical and university partners.<\/h3><\/div>We highly value the opinion of experts and are also prepared to break new ground. Thanks to the support of both the Federal Ministry of Education and Research (BMBF) and the Federal Ministry of Economics and Climate Protection (BMWK), we are also in a position to pursue these paths. <\/span><\/p>\n<\/div><\/div><\/div><\/i><\/i><\/span>ElastGraft<\/span><\/a><\/h4><\/div>\nProject Title:<\/h6>\nDevelopment of a natural vascular substitute for complete regeneration of deficient vessel sections based on porcine elastin-containing graft materials (ElastGraft) (FKZ: KK5025303NK1, BMWi)<\/h3>\n
Various vascular diseases such as arteriosclerosis with its sequelae, congenital vascular anomalies or injuries require conservative as well as sometimes surgical intervention. Surgical replacement of vessels can take place using various biomaterials. The problem is that the available materials cannot replicate the natural vessel architecture. The overall goal of this collaborative project is to develop an innovative natural-based vascular substitute for the complete regeneration and replication of complex vascular structures.<\/p>\n<\/div><\/div><\/div>
<\/i><\/i><\/span>Hemostasis through topological structures<\/span><\/a><\/h4><\/div>\nProject Title:<\/h6>\nHemomatrix<\/h3>\n
During the surgical procedure, bleeding is a disruption and sometimes even a challenge for the surgeon. On the one hand, blood loss must be limited, and on the other hand, blood obscures the view of the surgical area. In certain surgical areas, the choice falls on topological hemostats. The aim of this project is to develop an absorbable medical device that is able to reliably stop oozing and is also allowed to remain in the implantation site. <\/span><\/p>\n<\/div><\/div><\/div><\/i><\/i><\/span>Control options for resorption profiles<\/span><\/a><\/h4><\/div>\n\nThe need for control regarding resorption profiles of implants is the subject of our expert feedback. In our experience, a variety of factors affect the degradation behavior. Bacterial contamination in the wound cavity is one of the main causes leading to a change in the resorption profiles of our products. The overall objective of this project is to develop a control option to adjust the resorption profiles of biotrics products and their behavior towards enzymatic degradation and different wound situations. <\/span><\/p>\n<\/div>\n<\/div><\/div><\/div><\/i><\/i><\/span>Bone graft substitutes with defined release of active substances<\/span><\/a><\/h4><\/div>\nProject Title:<\/h6>\nOKEM (FKZ: 13GW0430A, BMBF).<\/h3>\n
Osteitis is one of the most common and serious nosocomial infections, occurring primarily through direct infection during bone surgery. Treatment is difficult and often associated with long-term, significant disadvantages for the patient, including amputations. OKEM aims to develop a technology for the functionalization of bone graft substitutes (KEM) that enables the controlled release of active substances in the body directly at the implanted KEM, thus reliably and efficiently counteracting nosocomial infection in the form of osteitis. <\/p>\n<\/div><\/div><\/div>
We highly value the opinion of experts and are also prepared to break new ground. Thanks to the support of both the Federal Ministry of Education and Research (BMBF) and the Federal Ministry of Economics and Climate Protection (BMWK), we are also in a position to pursue these paths. <\/span><\/p>\n<\/div><\/div><\/div> Various vascular diseases such as arteriosclerosis with its sequelae, congenital vascular anomalies or injuries require conservative as well as sometimes surgical intervention. Surgical replacement of vessels can take place using various biomaterials. The problem is that the available materials cannot replicate the natural vessel architecture. The overall goal of this collaborative project is to develop an innovative natural-based vascular substitute for the complete regeneration and replication of complex vascular structures.<\/p>\n<\/div><\/div><\/div> During the surgical procedure, bleeding is a disruption and sometimes even a challenge for the surgeon. On the one hand, blood loss must be limited, and on the other hand, blood obscures the view of the surgical area. In certain surgical areas, the choice falls on topological hemostats. The aim of this project is to develop an absorbable medical device that is able to reliably stop oozing and is also allowed to remain in the implantation site. <\/span><\/p>\n<\/div><\/div><\/div> The need for control regarding resorption profiles of implants is the subject of our expert feedback. In our experience, a variety of factors affect the degradation behavior. Bacterial contamination in the wound cavity is one of the main causes leading to a change in the resorption profiles of our products. The overall objective of this project is to develop a control option to adjust the resorption profiles of biotrics products and their behavior towards enzymatic degradation and different wound situations. <\/span><\/p>\n<\/div>\n<\/div><\/div><\/div> Osteitis is one of the most common and serious nosocomial infections, occurring primarily through direct infection during bone surgery. Treatment is difficult and often associated with long-term, significant disadvantages for the patient, including amputations. OKEM aims to develop a technology for the functionalization of bone graft substitutes (KEM) that enables the controlled release of active substances in the body directly at the implanted KEM, thus reliably and efficiently counteracting nosocomial infection in the form of osteitis. <\/p>\n<\/div><\/div><\/div><\/i><\/i><\/span>ElastGraft<\/span><\/a><\/h4><\/div>
Project Title:<\/h6>\n
Development of a natural vascular substitute for complete regeneration of deficient vessel sections based on porcine elastin-containing graft materials (ElastGraft) (FKZ: KK5025303NK1, BMWi)<\/h3>\n
<\/i><\/i><\/span>Hemostasis through topological structures<\/span><\/a><\/h4><\/div>
Project Title:<\/h6>\n
Hemomatrix<\/h3>\n
<\/i><\/i><\/span>Control options for resorption profiles<\/span><\/a><\/h4><\/div>
<\/i><\/i><\/span>Bone graft substitutes with defined release of active substances<\/span><\/a><\/h4><\/div>
Project Title:<\/h6>\n
OKEM (FKZ: 13GW0430A, BMBF).<\/h3>\n